
-
Ireland eye unlikely Six Nations title against uncertain Italy
-
Duterte's first ICC appearance set for Friday
-
From oil spills to new species: how tech reveals the ocean
-
Curry bags record 4,000th three-pointer as Warriors rout Kings
-
Hong Kong museum puts Picasso in cross-cultural dialogue
-
Alcaraz three-peat bid on track as Cerundolo downed
-
Chinese, Iranian, Russian diplomats meet for nuclear talks
-
England's Harry Brook banned from IPL for two years
-
Curry bags record 4,000th three-pointer as Warriors face Kings
-
Former sex worker records Tokyo's red-light history
-
Australians welcome departure of baby wombat grabber
-
Nepal community efforts revive red panda population
-
Norris fastest in first Australian GP practice, Hamilton 12th
-
Doncic drops 45 but Lakers pounded in Bucks loss
-
Most Asian markets rise on hopes for bill to avert US shutdown
-
ICC arrest, impeachment leave Duterte clan's political future in doubt
-
China deports Japanese tourists over Great Wall buttocks pic: reports
-
Swiatek to face Andreeva, Sabalenka meets Keys in Indian Wells semi-finals
-
Messi scores off the bench as Miami progress in Jamaica
-
War of words: Myanmar migrants face disinformation in Thailand
-
France eye 'supreme objective' of Six Nations as Scotland visit
-
Barca face Atletico rematch after defeat sparked unbeaten streak
-
Man City in Brighton test as Arsenal face Chelsea clash
-
Marseille face up to gulf separating them from PSG in France
-
England's Six Nations ambitions on the line against Wales
-
Take 'precautionary approach' on deep-sea mining: top official tells AFP
-
Renowned US health research hub Johns Hopkins to slash 2,000 jobs
-
Russian teen Andreeva focused on the job as WTA ranking rises
-
McIlroy tight-lipped about apologetic heckler incident
-
Panama 'firm' on canal as US reportedly weighs options
-
Four-song EP by late singer Faithfull to be released in April
-
You're kidding! Prince William reveals Aston Villa superstitions
-
Villegas, Spaun and Glover share Players lead, McIlroy one back
-
Top US university says ending 2,000 positions due to Trump cuts
-
Rangers down angry Mourinho's Fenerbahce to reach Europa League quarters
-
Brazil top court to consider Bolsonaro 'coup' case on March 25
-
Amorim 'proud' of Dorgu's honesty to overturn Man Utd penalty
-
Medvedev outlasts Fils to reach Indian Wells semi-finals
-
Fernandes sends Man Utd into Europa League quarters, Spurs advance
-
Rangers down Mourinho's Fenerbahce to reach Europa League quarters
-
Odobert double sends Spurs into Europa League quarter-finals
-
Fernandes hat-trick fires Man Utd into Europa League quarters
-
Duterte's first ICC appearance set for Friday: court
-
Stock markets tumble as Trump targets booze
-
Home is where hurt is as Duplantis misses out on new world record
-
Wales' Anscombe still eyeing 2027 World Cup despite Gatland doubts
-
Sea levels rise by 'unexpected' amount in 2024: NASA
-
Trump tariff threat leaves sour taste for European drinks producers
-
Defending champ Swiatek tops Zheng to reach Indian Wells semi-finals
-
Ex-NOAA chief: Trump firings put lives, jobs, and science in jeopardy

US greenlights pig kidney transplant trials
Two US biotech companies say the Food and Drug Administration has cleared them to conduct clinical trials of their gene-edited pig kidneys for human transplants.
United Therapeutics along with another company, eGenesis, have been working since 2021 on experiments implanting pig kidneys into humans: initially brain-dead patients and more recently living recipients.
Advocates hope the approach will help address the severe organ shortage. More than 100,000 people in the United States are awaiting transplants, including over 90,000 in need of kidneys.
United Therapeutics's approval, announced Monday, allows the company to advance its technology toward a licensed product if the trial succeeds.
The study authorization was hailed as a "significant step forward in our relentless mission to expand the availability of transplantable organs," by Leigh Peterson, the company's executive vice president.
The trial will initially enroll six patients with end-stage renal disease before expanding to as many as 50, United Therapeutics said in a statement. The first transplant is expected in mid-2025.
Meanwhile, rival eGenesis said it had received FDA approval in December for a separate three-patient kidney study.
"The study will evaluate patients with kidney failure who are listed for a transplant but who face a low probability of receiving a deceased donor offer within a five-year timeframe," the company said.
Xenotransplantation -- transplanting organs from one species to another -- has been a tantalizing yet elusive goal for science.
Early experiments in primates faltered, but advances in gene editing and immune system management have brought the field closer to reality.
Pigs have emerged as ideal donors: they grow quickly, produce large litters, and are already part of the human food supply.
United Therapeutics said trial patients would be monitored for life, assessing survival rates, kidney function, and the risk of zoonotic infections -- diseases that jump from animals to humans.
Currently, there is only one living human recipient of a pig organ: Towana Looney, a 53-year-old from Alabama who received a United Therapeutics kidney on November 25, 2024.
She is also the longest-surviving recipient, having lived with a pig kidney for 71 days as of Tuesday. David Bennett of Maryland received a pig heart in 2022 and survived 60 days.
J.Horn--BTB